The development of new antibiotics to treat infections caused by drug-resistant bacteria is "alarmingly slow," according to a report by the Infectious Diseases Society of America published in Clinical Infectious Diseases.
The report describes progress on IDSA's campaign launched in 2010, "10 × '20," which seeks to develop 10 new, safe and efficacious systemically administered antibiotics by 2020. The current report also shows progress since IDSA's 2009 report that outlined antibacterial drugs with the potential to treat infections caused by drug-resistant gram-negative bacilli — a certain type of bacteria.
Only two new antibiotics have been approved since its 2009 status report, the number of new antibiotics approved annually has decreased and several large pharmaceutical companies have withdrawn from antibacterial research and development, according to IDSA.
While IDSA found seven drugs in clinical development for treating infections caused by resistant GNB, none targets "the entire spectrum of clinically relevant GNB resistance," according to the report.
To speed the development of agents effective against antibiotic-resistant bacteria, IDSA recommends establishing financial incentives for pharmaceutical sponsors and building public-private partnerships to support antibacterial research and development.
5 Top Reasons Hospitals Misuse Antimicrobials
Study: Quality Improvement Methods Improve Appropriate Antibiotic Use
The report describes progress on IDSA's campaign launched in 2010, "10 × '20," which seeks to develop 10 new, safe and efficacious systemically administered antibiotics by 2020. The current report also shows progress since IDSA's 2009 report that outlined antibacterial drugs with the potential to treat infections caused by drug-resistant gram-negative bacilli — a certain type of bacteria.
Only two new antibiotics have been approved since its 2009 status report, the number of new antibiotics approved annually has decreased and several large pharmaceutical companies have withdrawn from antibacterial research and development, according to IDSA.
While IDSA found seven drugs in clinical development for treating infections caused by resistant GNB, none targets "the entire spectrum of clinically relevant GNB resistance," according to the report.
To speed the development of agents effective against antibiotic-resistant bacteria, IDSA recommends establishing financial incentives for pharmaceutical sponsors and building public-private partnerships to support antibacterial research and development.
More Articles on Antimicrobial Stewardship:
Study: Internet-Based Antimicrobial Stewardship Can Reduce Doses, Cost5 Top Reasons Hospitals Misuse Antimicrobials
Study: Quality Improvement Methods Improve Appropriate Antibiotic Use
